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Abstract
Human (gamma delta) γδ T cells are unconventional innate-like lymphocytes displaying a broad array of anti-tumor
activities with promising perspectives in cancer immunotherapy. In this context, Vδ2pos T cells represent the
preferential target of several immunotherapy protocols against solid tumors. However, the impact of both aging
and chemotherapy (CHT) on Vδ2pos T cells is still unknown. The present study evaluates with multi-parametric flow
cytometry the frequencies, terminal differentiation, senescence and effector-functions of peripheral blood and
tumor infiltrating Vδ2pos T cells purified from liver metastases (CLM) of patients affected by colorectal cancer (CRC)
compared to those of sex- and age-matched healthy donors. The peripheral blood of CLM patients underwent CHT
is characterized by decreased amounts of Vδ2pos T cells showing a relative increase of terminally-differentiated
CD27neg/CD45RApos (TEMRA) cells. The enrichment of this latter subset is associated with an increased expression of
the senescent marker CD57. The acquisition of CD57 on TEMRA Vδ2pos T cells is also coupled with impairments in
cytotoxicity and production of TNF-α and IFN-γ. These features resemble the acquisition of an immune-senescent
profile by Vδ2pos T cells from CLM patients that received CHT, a phenomenon that is also associated with the loss
of the co-stimulatory marker CD28 and with the induced expression of CD16. The group of CLM patients
underwent CHT and older than 60 years old showed higher frequencies of CD57pos and TEMRA Vδ2pos T cells. Similar
results were found for tumor infiltrating Vδ2pos T cell subset purified from CLM specimens of patients treated
with CHT. The toxicity of CHT regimens also affects the homeostasis of Vδ2pos T cells by inducing higher
frequencies of circulating CD57pos TEMRA subset in CLM underwent CHT and younger than 60 years old. Taken
together, our data demonstrate that the enrichment of senescent Vδ2pos T cells in CLM patients is not only induced
by patients’ aging but also by the toxicity of CHT that further accelerates the accumulation of CD57pos TEMRA cells
highly dysfunctional in their anti-tumor activities. These results are important to both predict the clinical outcome
of CLM and to optimize those protocols of cell cancer immunotherapy employing unconventional Vδ2pos T cells.
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Introduction
Human γδ T lymphocytes are divided in the two main
Vδ1pos and Vδ2pos subsets on the basis of their TCRδ-
chain repertoire. While Vδ1pos cells preferentially
localize in mucosal tissues and skin, Vδ2pos T cells are
mainly enriched in peripheral blood (PB) where they
represent about 5% of all circulating T cells. The acti-
vation of Vδ2pos T cells relies on the recognition of
non-peptidic compounds (i.e. microbial or stress- or
tumor-induced “phosphoantigens”) in association with
butyrophilin 3A1 (BTN3A1 also known as CD277). Be-
sides the TCR interactions with phosphoantigens/
BTN3A1 complexes, several Natural Killer Receptors
(NKRs) are involved in triggering the anti-tumor func-
tions of Vδ2pos T cells, with the C-lectin type NKG2D
playing a major role [1, 2]. The differential expressions
of CD27 and CD45RA surface markers identify
different Vδ2pos T cell subsets: CD27pos/CD45RApos




(TEM) and the terminally-differentiated (TEMRA)
CD27neg/CD45RApos cells. These Vδ2pos T cell subsets
diverge not only for their maturation/differentiation
status, but also for proliferative capacities, effector
functions and resistance to cell death in response to
antigens and/or cytokine stimulations [3].
Growing evidences highlighted the high impact of
Vδ2pos T cells in cancer immune-surveillance with
promising perspectives in cancer immunotherapy [4, 5].
In this context, two main clinical approaches have been
employed to boost anti-tumor activities of Vδ2pos T
cells. The first one activates them through the in vivo
administration of either IL-2 or synthetic nitrogen-
containing bisphosphonates (NBPs) drugs that, in turn,
induce intracellular accumulation of phosphoantigens. A
second strategy relies on adoptive transfers of Vδ2pos T
cells expanded in vitro with several methodologies such
as the activation with zoledronate [5, 6]. However, these
procedures showed both experimental and clinical limits
and many efforts are currently being implemented to
further improve the effector-functions and persistence
in vivo of Vδ2pos T cells. In this context, cellular senes-
cence is certainly one of the main issues to solve consid-
ering that age-related changes of T cells greatly impair
their capacity to expand and proliferate, thus leading to
dysfunctional immune responses against tumors and
pathogens [7]. The shift to senescence and accumulation
of mature T cells physiologically occur after 60 years old
when both αβ and γδ T lymphocytes lose their co-
stimulatory molecules (i.e. CD27 and CD28), acquire
terminally-differentiated TEM and TEMRA phenotypic
profiles, express high constitutive levels of the senes-
cence marker CD57 and shorten their telomerase
lengths [8–11]. However, it is still controversial whether
CD57 can be used as a single marker to identify senes-
cent Vδ2pos T cells regardless of differential expression
of CD27 and CD45 [3, 11, 12].
Aging is certainly a major burden for social health
systems in the industrialized countries as the popula-
tions are longer exposed to several pro-tumorigenic
risk factors. This leads to a significant higher incidence
of cancer onsets in the 6th, 7th and 8th decades of life
[13]. Hence, there are rising numbers of elderly pa-
tients undergoing anti-cancer conventional chemother-
apies (CHT), whose high toxicities greatly hamper
both duration and quality of life. In this regard, several
lines of clinical and experimental evidence pointed out
that these anti-neoplastic treatments further accelerate
immune-cell senescence, thus representing negative
prognostic factors in aging and worsening the overall
clinical outcomes of cancer patients [14, 15].
Since the use of Vδ2pos T cells is currently consid-
ered one of the most promising tools in cancer im-
munotherapy [4, 5], understanding the exact impact of
CHT on their immune-senescence is key to better pre-
dict the clinical outcomes of cancer in elderly and to
optimize those therapeutic protocols targeting these
highly cytotoxic unconventional T cell effectors. Colo-
rectal cancer (CRC) represents the 3rd most frequent
solid cancer and more than 50% of CRC patients
undergo hepatic dissemination of the primary tumor. The
gold-standard therapeutic approach of CRC patients with
liver metastasis (CLM) is the surgical removal of hepatic
secondary lesions after neoadjuvant combination CHT
with or without biological therapy (BT) (Table 1) [16, 17].
Moreover, a higher infiltration of competent immune cells
in tumor mass greatly improves the prognosis of CLM pa-
tients and increases their overall survival (OS) [18, 19].
Here, we analyze the impact of conventional CHT regi-
mens on the homeostasis and effector-functions of Vδ2pos
T cells in a cohort of CLM elderly patients.
Methods
Patients and specimen collections
Biological specimens from CLM patients underwent CHT
(n = 58), or from CHT naïve patients (n = 13) and aged-
and sex-matched healthy donors (n = 40) (Table 1).
Patients’ recruitment was performed according to the Dec-
laration of Helsinki and the protocol had been approved by
the Institutional Review Board (IRB) of Humanitas Re-
search Hospital (HRH) (Approval N.168/18). All enrolled
patients signed the related consent forms. Liver specimens
and peripheral blood mononuclear cells (PBMCs) were iso-
lated and stored as we previously described [19, 20].
Flow cytometry
Absolute γδ T cell counts were performed on 100 μl of
fresh PB stained with following anti-human monoclonal
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antibodies (mAbs): CD3 (SK7; BV605) and CD45 (H130;
AF700) (BioLegend) and Vδ2 (IMMU-389; FITC) (Beck-
man Coulter). We then used CountBright™ Absolute
Counting Beads (Invitrogen) according to the manufac-
turer’s instructions.
For both regular and intracellular staining, γδ T cells
were first screened for viability with Zombie Aqua™ Fixable
Viability kit (BioLegend) and then processed as previously
described [20]. The following mAbs were used: CD28
(CD28.2; PE-Cy7) (BioLegend); Vδ2 (B6; BUV395), CD3
(UCHT1; BUV661), CD45RA (H100; BUV737), CD16 (348;
BUV496) (BD); CD57 (REA769; PE-Vio615) (Miltenyi);
CD27 (0322; APCeFluor780) (eBioscience). The intracellu-
lar amounts of TNF-α (Mab11; PE) and IFN-γ (B27; Bv711)
(BD) as well as the frequency of cytotoxic CD107apos cells
(H4A3, PE) (BD Biosciences) was evaluated after stimulat-
ing γδ T cells with Phorbol myristate acetate (PMA; 0.5 μg/
mL) and Ionomycin (0.1 μg/mL) (Sigma Aldrich).
Flow cytometry experiments were performed on FACS
Symphony™ (BD). All data and t-SNE algorithm were ana-
lyzed with FlowJo Software (version 9.6) (FlowJo LLC)
using single stained controls BD CompBeads™ (BD).
Statistical analyses
The data were assessed by non-parametric Mann-Whitney
U (unpaired) or Wilcoxon (matched-paired) tests by using
GraphPad Prism version 7. For all correlation analysis
Pearson’s coefficient was applied. Statistically significant p
values were represented with GraphPad (GP) style and
summarized with following number of asterisks (*): *P
≤0.05; **P ≤0.01; ***P ≤0.001; ****P ≤0.0001.
Results
Vδ2pos T cells were gated within viable CD3pos/CD45pos
lymphocytes and their absolute counts are significantly
lower in the PB of CLM patients underwent CHT com-
pared to those of healthy donors (Fig. 1a-b). We then
analyzed the surface expression of CD27 and CD45RA
to track the differentiation and distribution of Vδ2pos T
cell subsets. Our data showed a significant increase of
Vδ2pos TEMRA in CLM patients underwent CHT (28.9 ±
20.6%) compared to healthy controls (9.4 ± 6.4%). This
phenomenon is associated with the previous administra-
tion of CHT, as the frequency of circulating Vδ2pos
TEMRA in those CLM patients naïve for CHT (16.7% ±
12.6) is similar to that of healthy donors and significantly
lower to that of CLM patients underwent CHT (41.6% ±
19.6). The increased amounts of Vδ2pos TEMRA in CLM
patients treated with CHT is counterbalanced by a sig-
nificant decrease of Vδ2pos TCM in the same patients
compared to their counterparts naïve for CHT (Fig. 1c-
d-e). The great impact of neoadjuvant CHT in shaping
the distribution of Vδ2pos T cell subsets in CLM patients
is also confirmed by our findings showing that the num-
ber of CHT cycles (8.7 ± 2.7) inversely correlates with
the percentages of PB Vδ2pos TCM, while not affecting at






(mean number ± SD)
CHT/BT Regimensa 58 82 8.7 ± 5.3
Combination Therapy with Biologicals
FOLFOX + VEGF-A mAb 12 21.5 7.7 ± 1.4
FOLFIRI + EGFR mAb 11 19.0 11.7 ± 4.3
FOLFIRI + VEGF-A mAb 10 17.2 7.5 ± 3.3
FOLFIRI + FOLFOX + VEGF-A mAb 7 12.0 13.0 ± 3.2
FOLFOX + EGFR mAb 6 10.3 11.0 ± 2.3
XELOX + VEGF-A mAb 4 6.9 8.5 ± 3.4
Combination Therapy without Biologicals
FOLFOX 4 6.9 5.0 ± 1.6
XELOX 2 3.4 4.6 ± 1.2
FOLFIRI 2 3.4 7.0 ± 6.0
Naïve for CHT 13 18 0.0
Total Patients 71
FOLFOX: 5-fluorouracil/oxaliplatin; XELOX: capecitabine/oxaliplatin; FOLFIRI: 5-fluorouracil/irinotecan
EGFR mAb Epidermal Growth Factor Receptor inhibitor monoclonal antibody
VEGF-A mAb Vascular Endothelial Growth Factor A monoclonal antibody
aNote:
a) All CLM patients completed their last CHT cycle at least 6 weeks before the blood draws used for our experiments and before surgical procedures
b) The table refers all therapies received by CLM patients before surgery
c) More than 91% of all CLM patients received one line therapy and all other patients received two lines (1st and 2nd) combination therapy: 3 patients received 1st
FOLFOX and 2nd FOLFIRI + VEGF-A; 1 patient received 1st FOLFIRI + VEGF-A and 2nd FOLFOX + VEGF-A, and 1 patient received 1st FOLFIRI + VEGF-A and 2nd FOLFOX
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all the overall frequencies of PB Vδ2pos TEMRA (Fig. 1f).
This latter dichotomy reflects the different homeostatic
status of Vδ2pos TCM compared to that of Vδ2
pos TEMRA,
as the first subset is composed of proliferating lympho-
cytes high susceptible to the toxicity of those chemo-
therapy compounds that kills all dividing cells without
any specificity against tumor blasts. Instead, TEMRA
Vδ2pos cells are terminally differentiated and not prolif-
erating effectors resistant to CHT, thus explaining their
high frequency even after several cycles of neoadjuvant
anti-tumor chemotherapies.
The relative increased frequency of PB TEMRA Vδ2
pos in
CLM patients underwent CHT correlates with their
higher expression of CD57. Notably, the expression of this
latter marker of immune senescence follows the terminal
differentiation of Vδ2pos T cells. Indeed, the frequency of
PB CD57pos TEMRA Vδ2
pos T cells resulted significantly
higher compared to that of CD57pos TEM Vδ2
pos T cells
that, in turn, showed significantly higher amounts of
CD57 when compared to TCM Vδ2
pos T cells (Fig. 2a-b).
The acquisition of CD57 by terminal-differentiated Vδ2pos
T cells is also associated with significantly impaired
effector-functions in term of anti-tumor cytokines produc-
tion (i.e. IFN-γ and TNF-α) and ability to degranulate (i.e.
decreased amounts of cytotoxic CD107apos cells) when
compared to CD57neg/Vδ2pos T cells (Fig. 2c). Taken to-
gether, these data indicate that the PB of CLM patients
underwent CHT is highly enriched of senescent CD57pos/
TEMRA Vδ2
pos T cells dysfunctional in their anti-tumor ef-
fector functions.
To assess the impact of patients’ aging in the higher
frequencies of CD57pos and TEMRA Vδ2
pos T cells in
Fig. 1 Frequency and distributions of peripheral blood Vδ2pos T cell subsets in patients affected by liver metastasis of colorectal cancer and
underwent chemotherapy. a Representative dot plot flow cytometric graphs showing the gating strategy of viable CD45pos/CD3pos/Vδ2pos T
lymphocytes. b Statistical dot plot graph showing the absolute number of CD3pos (left) and Vδ2pos (right) T cells per 1 mL of blood in healthy
donors (n = 12; mean age: 49.3 ± 9.5) and CLM patients underwent CHT regimens (n = 16; mean age: 51.5 ± 8.1). c-e Representative dot plot graph
flow cytometric graph (c) and pie charts (d and e) showing respectively the distribution and the percentages of CD27pos/CD45RApos TNaive (upper
right in dot plot graph and light green in pie charts), CD27pos/CD45RAneg central memory (TCM) (upper left in dot plot graph and gray in pie
charts), CD27neg/CD45RAneg effector-memory (TEM) (lower left in dot plot graph and purple in pie charts) and terminally-differentiated CD27
neg/
CD45RApos (TEMRA) (lower right in dot plot graph and orange in pie charts) Vδ2pos T cell subsets. Pie charts compare the frequencies of Vδ2pos T
cell subsets between healthy donors (n = 34; mean age: 51.7 ± 10.8) with age-matched CLM patient underwent CHT (n = 33; mean age: 51.5 ± 8.1)
d as well as between CLM patients naïve for CHT (n = 13; mean age: 69.5 ± 8.1) and age-matched CLM patients underwent CHT (n = 41; mean age:
70.1 ± 6.5) (e). f Statistical analysis showing the Pearson correlations between the frequency (%) of either TCM (left) or TEMRA (right) Vδ2pos T cells
with the number of CHT cycles (mean number: 8.7 ± 6.5) administered to patients affected by CLM (n = 40)
Bruni et al. Journal for ImmunoTherapy of Cancer           (2019) 7:347 Page 4 of 8
CLM patients underwent CHT, we divided this cohort
in subjects younger or older than 60 years old. Our data
confirmed that the age-induced immune-senescence
significantly increases the percentages of both CD57pos
and TEMRA Vδ2
pos T cells in those patients > 60 years
old (Fig. 2d). We also showed that CHT alone induces
immune-senescence regardless of patients’ age. Indeed,
the percentage of CD57pos TEMRA Vδ2
pos cells resulted
significantly higher in those CLM underwent CHT and
younger than 60 years old compared to that of age-
matched healthy donors (Fig. 2e). These data clearly in-
dicate that both CHT and aging play synergic roles in
the regulation of Vδ2pos T cell homeostasis in CLM pa-
tients with the final result of greatly accelerating their
terminal differentiation towards a senescent CD57pos/
TEMRA subset highly impaired in its anti-tumor effector-
functions. We also demonstrate here that the acquisition
of CD57 inversely correlates with the surface expression
of CD28 while being associated with increased surface
amounts of CD16 (Fig. 2f), the FcγRIII receptor known
to define highly differentiated human Vδ2pos TEMRA cells
[21]. The clustering of CD57pos/Vδ2pos TEMRA co-
expressing CD16 and lacking CD28 in CLM patients
underwent CHT is confirmed and better visualized by
the t-Distributed Stochastic Neighbor Embedding (t-
SNE) analysis (Fig. 3a). This analytic approach also
allowed us to compare the impact of CHT in inducing
high frequencies of PB CD57pos/CD16pos/CD28neg/
Vδ2pos TEMRA cells in CLM patients compared to those
of age-matched healthy donors (Fig. 3b).
Although the overall frequency of tumor infiltrating
Vδ2pos T cells purified from CLM specimens is not
Fig. 2 Senescence of peripheral blood Vδ2pos T cell in patients affected by liver metastasis of colorectal cancer and underwent chemotherapy. a
Statistical analysis showing the correlations between the frequencies (%) of Vδ2pos TEMRA and CD57pos/Vδ2pos T and in CLM patients underwent
CHT (n = 40). b Statistical dot plot (left) and representative histogram (right) graphs showing the expressions (%) of CD57 on matching TCM, TEM
and TEMRA Vδ2pos T cell subsets in CLM patients underwent CHT (n = 15). c Statistical bar graphs showing the fold change increases of CD107a
expression as well as of intracellular amounts of IFN-γ and TNF-α by CD57neg and CD57pos Vδ2 T cell effector subsets (i.e. TEMRA and TEM) from
CLM patients underwent CHT and following in vitro stimulation with PMA and Ionomycin (n = 6). d Statistical dot plot analysis showing the
expressions (%) of CD57 and the frequencies (%) of TEMRA within Vδ2pos T cell compartments in CLM patients underwent CHT and divided in two
groups of respectively < (white circles; n = 18) and≥ (black circles; n = 21) of 60 years old. The mean age of the entire cohort of CLM patients
underwent CHT is of 61 ± 10.7 years old as shown in statistical graph on right upper side. e Statistical dot plot analysis showing the expressions
(%) of CD57 on Vδ2pos TEMRA cells from CLM patients underwent CHT and under 60 years old (n = 16) compared to age-matched healthy donors
(n = 16). f Statistical analysis showing the correlations between the surface levels (%) of CD57 and CD28 (n = 51) (left graph) or CD16 (n = 51)
(right graph) on Vδ2pos T cells in CLM patients underwent CHT
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affected by the administration of CHT, we found a sig-
nificant increase of CD57 expression on those Vδ2pos
T cells from patients underwent CHT compared to
naïve ones (Fig. 3c). Similar to their PB counterparts,
the frequency of CD57pos/Vδ2pos T cells is significantly
higher in elderly CHT patients ≥60 years old (Fig. 3d).
Consistently with these data, t-SNE analysis showed
also in CLM specimens of patient administered with
CHT an increased frequency of age-related tumor infil-




The present study is aimed to measure the true impact of
conventional CHT regimens on unconventional T cell
senescence in elderly cancer patients, since the toxicity of
conventional anti-tumor therapies greatly impairs their abil-
ity to clearance malignant cells [7, 12, 14, 15]. In particular,
we focused our investigations on circulating Vδ2pos cells
that are endowed with great anti-tumor potentials currently
being targeted by several protocols of cancer immunother-
apies [4–6]. Our data showed that CLM patients underwent
CHT, although showing lower absolute counts of circulat-
ing Vδ2pos cells, retain high relative frequencies of termin-
ally differentiated and senescent CD57pos/CD28neg/CD16pos
TEMRA Vδ2
pos cells greatly impaired in their effector-
functions. This latter subset is resistant to the toxicity
exerted by repeated CHT cycles administering DNA-
damaging drugs that, in contrast, are highly toxic against
less differentiated and still proliferating TCM Vδ2
pos cells.
Fig. 3 Clustering of peripheral blood and tissue infiltrating senescent CD57pos/CD28neg/CD16pos TEMRA Vδ2pos T cells in patients affected by liver
metastasis of colorectal cancer and underwent chemotherapy. a t-SNE analysis plots in CLM patients underwent CHT (n = 16) showing the cluster
of PB CD57pos/ Vδ2pos T cells (red, upper left plot) co-expressing CD16 (blue, upper right plot), CD45RA but not CD27 (TEMRA in green, lower left
plot) and negative for CD28 (black, lower right plot). b t-SNE analysis plots (left) and statistical dot plot graph (right) showing the frequency (%)
of senescent PB CD57pos/CD28neg/CD16pos TEMRA Vδ2pos T cells in healthy donors (upper plot; n = 12; mean age: 51.7 ± 10.8) and CLM underwent
CHT (lower plot; n = 16; mean age: 61 ± 10.7). c Summary dot plot analysis showing the frequencies (%) of liver tumor-associated Vδ2pos T cells
within total CD3pos T lymphocytes or CD57pos/Vδ2pos T cells in CLM patients receiving CHT regimen (black circles; n = 58) and naïve for CHT
(white circles; n = 13). d Statistical dot plot analysis showing the frequencies (%) of CD57pos cells on liver tumor infiltrating Vδ2pos T cells in CLM
patients underwent CHT regimen and sub-divided in two groups of respectively < (white circles; n = 22) and≥ (black circles; (n = 27) of 60 years
old. e t-SNE analysis plots (left plots) and statistical chart (right graph) of the CHT-mediated changes in the frequency (%) of the age-related, liver
tumor infiltrating CD57posCD28negCD16posTEMRA Vδ2
pos T cell cluster in CHT treated CLM patients (lower plot, n = 25; mean age: 61 ± 10.7) and
naïve for CHT patients (upper plot, n = 13; mean age: 69.5 ± 8.1)
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The preferential accumulation in PB of senescent
CD57pos TEMRA Vδ2
pos cells in CLM patients underwent
CHT is associated with two major mechanisms. The first
one is linked to natural immune-senescence of people
aging as the incidence of many cancers is higher in pa-
tients ≥ of 60 years old. In this context, liver metastatic
CRC is one of the most common causes of cancer deaths
worldwide with a higher incidence in elderly [16, 17]. In-
deed, our cohort of recruited CLM subjects had a mean
age of 61 ± 10.7 years old and both the frequencies of
CD57pos and TEMRA Vδ2 T cell subsets resulted higher
in that fraction of patients older than 60 years. The sec-
ond mechanism is associated with a direct toxicity of
CHT on immune cells, as also highlighted by several
studies both in pediatric and geriatric cancer patients
[14, 15, 22]. As a matter of fact, we show here that the
expression of CD57 on TEMRA Vδ2
pos cells is much
higher on those CLM patients underwent CHT and
younger than 60 years old compared to age-matched
healthy donors. This demonstrates that neoadjuvant
CHT induces immune senescence also on unconven-
tional T cells regardless of CLM patients’ age. Notably,
high frequencies of impaired CD57pos/TEMRA Vδ2
pos cells
were able to persist in PB of CLM patients even after 6
weeks from the completion of the last CHT cycle and
before surgical removal of liver metastases. Further pro-
spective studies are required to assess how long senescent
and functional impaired Vδ2pos T cells survive after CHT
and what clinical impact they have on the OS of CLM pa-
tients. In this regard, it has been already reported that the
enrichment of circulating subsets of CD57pos αβ T cells
represents a negative prognostic factor in the clinical out-
come of gastrointestinal cancers [23].
Our study also contributes to better characterize
immune-senescence of Vδ2pos T cells, since it has been
recently reported that expression of CD57 can define
alone their senescent status without the need of also
evaluating the expression of both CD27 and CD45RA
[11]. This represents a key point that is currently being de-
bated both in physiological and pathological conditions.
We found that, at least in a human cancer setting, the
expression of CD57 on senescent Vδ2pos T cell parallels
their terminal differentiation towards TEMRA (CD27
neg/
CD45RApos), a phenomenon associated with the loss of
CD28 and the acquired expression of CD16. These results
are in line with a previous study showing that Vδ2pos
TEMRA are refractory to phosphoantigen stimulation, but
rather respond to activation via FcγRIII [21].
The majority of cancer patients are older than 65 years
old in line with population aging [14]. In this context,
several clinical trials in the elderly are currently being
implemented to optimize the anti-tumor activities of un-
conventional T cells. These therapeutic protocols are
mostly aimed to expand Vδ2pos T cells both in vivo and
in vitro [6]. Hence, a better understanding of the mecha-
nisms accelerating immune-senescence in aging is
fundamental to boost the effector-functions of these
cytotoxic and cytokine-producer T lymphocytes. We
show here that, neoadjuvant CHT regimens, although
absolutely required to reduce tumor mass in CLM pa-
tients before surgery, greatly speed the senescence of
Vδ2pos T cells in synergy with aging of cancer patients.
This knowledge will allow us to better optimize
immune-therapies against cancers in elderly. Indeed,
senescence process can be reversed through the inhib-
ition of p38 mitogen-activated protein kinase (MAPK)
signaling [24]. This methodology could be then
approached to develop new protocols implementing pre-
treatment with MAPK inhibitors in elderly patients with
CRC [25]. Alternatively, new methodology can be imple-
mented in vitro to select and expand CD57neg/Vδ2pos T
cells that better resist to the terminal differentiations
and senescence induced by CHT. Further studies are
also required to better identify those CHT associated ac-
cumulation of impaired and senescent circulating Vδ2pos
T cells.
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